Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer

被引：0
|
作者：
He, Yong [1 ]
机构：
[1] Third Mil Med Univ, Daping Hosp, Chongqing, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 373卷 / 06期
关键词：
METFORMIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：578 / 578
页数：1
相关论文
共 50 条
  • [21] Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer
    Melosky, B.
    Banerji, S.
    Blais, N.
    Chu, Q.
    Juergens, R.
    Leighl, N. B.
    Liu, G.
    Cheema, P.
    [J]. CURRENT ONCOLOGY, 2020, 27 (02) : E146 - E155
  • [22] Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer
    Alex Martinez-Marti
    Enriqueta Felip
    Francesco Mattia Mancuso
    Ginevra Caratú
    Judit Matito
    Paolo Nuciforo
    Irene Sansano
    Nely Diaz-Mejia
    Susana Cedrés
    Ana Callejo
    Patricia Iranzo
    Nuria Pardo
    Josep Maria Miquel
    Alejandro Navarro
    Ana Vivancos
    Miriam Sansó
    [J]. British Journal of Cancer, 2021, 125 : 1561 - 1569
  • [23] Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Mambetsariev, Isa
    Arvanitis, Leonidas
    Fricke, Jeremy
    Pharaon, Rebecca
    Baroz, Angel R.
    Afkhami, Michelle
    Koczywas, Marianna
    Massarelli, Erminia
    Salgia, Ravi
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [24] Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
    Baik, Christina S.
    Chamberlain, Marc C.
    Chow, Laura Q.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : 1268 - 1278
  • [25] Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study
    Peng, Duanyang
    Liang, Pingan
    Zhong, Congying
    Xu, Peng
    He, Yanqing
    Luo, Yuxi
    Wang, Xia
    Liu, Anwen
    Zeng, Zhimin
    [J]. BMC CANCER, 2022, 22 (01)
  • [26] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Ken Uchibori
    Naohiko Inase
    Mitsugu Araki
    Mayumi Kamada
    Shigeo Sato
    Yasushi Okuno
    Naoya Fujita
    Ryohei Katayama
    [J]. Nature Communications, 8
  • [27] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Uchibori, Ken
    Inase, Naohiko
    Araki, Mitsugu
    Kamada, Mayumi
    Sato, Shigeo
    Okuno, Yasushi
    Fujita, Naoya
    Katayama, Ryohei
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [28] Clinical Benefit of EGFR-TKIs Plus Radiotherapy for Treating EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer
    Li, T.
    Wang, R.
    Lv, J.
    Sun, C.
    Shi, Q.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E516 - E517
  • [29] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [30] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    [J]. British Journal of Cancer, 2019, 121 : 725 - 737
12345